PRESS RELEASES

Malaysia Welcomes SweeGen’s Bestevia® Zero-Calorie Stevia Sweeteners for Food and Beverages

The health authority acceptance opens doors to creative brand innovation and renovation of sugar products.

Rancho Santa Margarita, May 04, 2021 (GLOBE NEWSWIRE) — As pandemic conditions have encouraged Asian consumers to adopt healthier lifestyles and diets, the Malaysia Ministry of Health officially accepted SweeGen’s zero-calorie Bestevia sweeteners, Rebaudiosides D, E and M for use as ingredients in food and beverage products.

Brands in Asia are striving to deliver sweet indulgence alongside new and exciting flavors in snacks and beverages to satisfy consumers’ cravings. The acceptance of not just one, but three of SweeGen’s premium stevia ingredients, gives brands in Malaysia the creative latitude to tackle sugar challenges when innovating and renovating products.

“Cutting calories and adopting nature-based ingredients in diets has long fit into the importance of health and wellness for consumers in Asia,” said Senior Vice President of Sales, Luca Giannone. “Our promise well into the future is to ultimately move the needle in what consumers eat and drink through better sugar reduction solutions.”

Malaysia is one of many APAC countries where SweeGen’s non-GMO stevia sweeteners will change the landscape for offering a low cost-in-use sugar reduction solution.

In its quest to provide highest levels of customized service to brands and the broadest toolbox of taste solutions in Asia, SweeGen is in the process of opening a food and beverage application center in Singapore to collaborate with brands on exploring and discovering product innovations motivated by consumer trends and regional tastes.  Last year, Singapore’s food safety authority approved SweeGen’s Rebs D and E in 2020 and Reb M in 2019.

Next generation non-GMO stevia sweeteners have led the way in replacing sugar in foods and beverages, nutritional products, and many other market products world-wide. In a Mintel 2020 report on table sauces, it reported that “consumers in this region are increasingly keen to eat more natural foods. This should encourage table sauce brands to remove artificial additives and prioritize natural, organic, and less-processed ingredients.” SweeGen’s proprietary zero-calorie stevia sweeteners are produced through a patented bioconversion process, which begins with the stevia leaf to achieve high-purity clean-tasting Rebs D, E and M.

SweeGen offers food and beverage manufacturers rapid innovation sugar reduction solutions for beverage, dairy, savorybakery and confectionery. Bestevia Rebs D, E and M were commercialized in the past few years, and have already been approved in many regions around the world.

“This regulatory milestone is just one of many achievements in APAC, said Director of Regulatory Affairs, Hadi Omrani. “We’re looking forward to continuing our goal throughout the region which will help an industry that strives to be relevant with consumers.”

About SweeGen

SweeGen provides sweet taste solutions for food and beverage manufacturers around the world.

We are on a mission to reduce the sugar and artificial sweeteners in our global diet.  Partnering with customers, we create delicious zero-sugar products that consumers love.  With the best next generation stevia sweeteners in our portfolio such as Bestevia® Rebs B, D, E, I, M, and N, along with our deep knowledge of flavor modulators and texturants, SweeGen delivers market-leading solutions that customers want and consumers prefer.

For more information please contact [email protected] and visit SweeGen’s website, www.sweegen.com.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains forward-looking statements, including, among other statements, statements regarding the future prospects for Reb M stevia leaf sweetener. These statements are based on current expectations, but are subject to certain risks and uncertainties, many of which are difficult to predict and are beyond the control of SweeGen, Inc.

Relevant risks and uncertainties include those referenced in the historic filings of SweeGen, Inc. with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and therefore should be carefully considered. SweeGen, Inc. assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.

Attachments

Ana Arakelian
SweeGen
+1.949.709.0583
[email protected]

Latest News

Huber ลงนามในข้อตกลงเพื่อเข้าซื้อหุ้นที่เหลือในการร่วมลงทุน MAGNIFIN

แอตแลนตา, May 07, 2021 (GLOBE NEWSWIRE) — เมื่อวันที่ 4 พฤษภาคม J.M. Huber Corporation (ต่อไปนี้จะเรียกว่า “Huber”) ได้ลงนามข้อตกลงขั้นสุดท้ายกับ RHI Magnesita (ต่อไปนี้จะเรียกว่า “RHIM”) เพื่อเข้าถือหุ้น 50% ในการร่วมลงทุนแบบ 50/50 ของบริษัท MAGNIFIN Magnesiaprodukte GmbH & Co. KG (ต่อไปนี้จะเรียกว่า “MAGNIFIN”) การทำธุรกรรมนี้คาดว่าจะปิดลงในช่วงครึ่งหลังของปี 2021 ซึ่งอยู่ระหว่างการอนุมัติตามกฎข้อบังคับ แรกเริ่มนั้น Huber ได้รับผลประโยชน์จากการเป็นเจ้าของ MAGNIFIN 50% ซึ่งเป็นส่วนหนึ่งของการซื้อกิจการ Martinswerk จาก Albemarle ในปี 2016 Martinswerk ตั้งอยู่ในเมืองแบร์กไฮม์ ประเทศเยอรมนีกลายเป็นส่วนหนึ่งของหน่วยธุรกิจเชิงกลยุทธ์ (SBU) ของ Huber Engineered Materials (HEM) […]

Philips Annual General Meeting of Shareholders approves all proposals

May 6, 2021 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) announced that today’s Annual General Meeting of Shareholders (2021 AGM) has re-appointed Mr. Marnix van Ginneken as member of the Board of Management and appointed Mrs. Chua Sock Koong and Mrs. Indra Nooyi as members of the Supervisory Board. The other proposals voted on […]

Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02

Seattle, May 06, 2021 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with Oculis to manufacture OCS-02, a Phase II investigational drug targeting both Dry Eye Disease and Anterior Uveitis, at its Heidelberg facility. “We are very pleased that Oculis has chosen us to […]

Bombardier Reports First Quarter 2021 Financial Results, Affirms Full Year Financial Guidance and Delivery Outlook

Business jet revenues of $1.3 billion, up 18% year-over-year, mainly driven by a favourable mix of large-cabin aircraft deliveries, including eight Global 7500 aircraft Adjusted EBITDA(1) from continuing operations of $123 million, up 43% year-over-year, reflecting an improved aircraft mix, Global 7500 aircraft learning curve progress and cost structure improvements; adjusted EBIT(1) from continuing operations […]